A XM não fornece serviços a residentes nos Estados Unidos da América.

BNP’s AXA deal is a logical use of spare cash



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BREAKINGVIEWS-BNP’s AXA deal is a logical use of spare cash</title></head><body>

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

By Neil Unmack

LONDON, Aug 2 (Reuters Breakingviews) -BNP Paribas BNPP.PA investors will be heaving a sigh of relief. Ever since the $75 billion French bank finalised its sale of U.S. arm BancWest last year, the risk has been that CEO Jean-Laurent Bonnafé gets tempted to do something silly with the proceeds. Thursday’s 5.1 billion euro swoop for AXA’s AXAF.PA asset management arm, in contrast, looks agreeably logical.

Bonnafé’s BancWest disposal left him with 8 billion euros to spend, net of share buybacks. That raised the danger he might fritter it away on a bad lending splurge, or a rash swoop on an ill-fitting fellow bank. With BNP trading at a mere 0.65 times estimated 2024 tangible book value, as per LSEG data, investors’ first choice might be a bigger buyback of cheap shares.

Asset management deals are far from strife-free. The integration process can see key portfolio managers leave, or consultants freeze allocations. BNP is also buying a bigger business than the one it already possesses: AXA IM’s assets under management will comprise 850 billion euros of the 1.5 trillion euro combined operation.

Still, Bonnafé is not paying too rich a price. Annualising first-half figures, BNP Paribas is forking out just shy of 13 times annual earnings. That’s more than the level at which European asset manager peers like Amundi AMUN.PA or DWS DWSG.DE trade, but in line with Jefferies’ average multiple for recent asset management deals of 14 times.

Moreover the deal, which allows AXA to slim down and focus capital on traditional insurance, gives BNP a much-needed leg up in asset management. The combined BNP-AXA business will have a credible presence in hot areas like credit, and scale to help compete with the likes of Amundi. Falling rates should also drive business to asset managers that can demonstrate they can make decent returns.

Better still, it’s an area that chews up less capital and is less heavily penalised than ordinary banking by regulators in stress tests. While the deal may cost over 5 billion euros, BNP estimates the new business will only consume about 25 basis points of its common equity, or around 1.8 billion euros. Barclays analysts reckon part of the difference may be down to the so-called “Danish compromise”, European capital rules which allow banks with insurance arms – like BNP – to hold less capital.

Either way, on that basis AXA’s roughly 360 million euros of earnings last year would generate a return on capital well above 15%, even before factoring in cost savings. Jefferies pegs BNP Paribas’ own return on tangible equity at about 11% this year. As such, Bonnafé could have found worse ways to flash his cash.

Follow @Unmack1 on X


CONTEXT NEWS

BNP Paribas on Aug. 1 said it had entered into exclusive talks to buy AXA Investment Management for 5.1 billion euros from French insurer AXA.

BNP said it will acquire AXA IM through its Cardif insurance business, and merge it with BNP Asset Management, creating a fund group with 1.5 trillion euros of assets. The unit will also run AXA’s long-term savings business. The deal will generate an 18% return on invested capital after three years, the French bank said.

In a separate statement, AXA said the deal would also comprise a further 300 million euros for the sale of fund unit Select, bringing the total outlay to 5.4 billion euros.

BNP Paribas shares were trading at 60.7 euros as of 0826 GMT on Aug. 2, down 1.3%. The STOXX index of leading European stocks was off 1.4%, while AXA shares were trading at 32.4 euros, up 1.8%.


Graphic: France’s fund giants https://reut.rs/3SzGifw


Editing by George Hay and Oliver Taslic

</body></html>

Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.

Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.

Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.

Aviso de risco: O seu capital está em risco. Os produtos alavancados podem não ser adequados para todos. Recomendamos que consulte a nossa Divulgação de Riscos.